Galectin Therapeutics reported Q3 FY2025 results with a reduced net loss and provided an update on the NAVIGATE trial for belapectin, highlighting encouraging biomarker data and submission to the FDA. The company believes it has sufficient cash to fund operations through June 2026.
New NAVIGATE data presented at AASLD further strengthen the clinical and mechanistic profile of belapectin, showing durable antifibrotic activity.
positiveBelapectin demonstrated consistent, meaningful effects across multiple key biomarkers in MASH cirrhosis, including reductions in liver stiffness and fibrosis risk.
positiveTreatment with belapectin was associated with a reduced presence of clinically significant portal hypertension and a lower risk of hepatic decompensation.
positiveNet loss for the quarter decreased to $8.2 million, or ($0.13) per share, compared to $11.2 million, or ($0.18) per share in the prior year.
positiveResearch and development expenses decreased significantly to $2.6 million from $7.6 million in the prior year due to trial timing.
positiveThe company has sufficient cash and a new line of credit to fund operations through June 30, 2026.
positiveThe company reported a net loss of $8.2 million for the quarter and a total stockholders' deficit of $125.3 million.
negativeTotal liabilities increased significantly to $136.4 million as of September 30, 2025, from $120.6 million at the end of 2024.
attentionCash and cash equivalents decreased to $11.5 million from $15.1 million at the end of 2024.
attentionMargin metrics will be available once backend extracts data from insights_json
The company submitted the NAVIGATE data package to the FDA and requested feedback on proposed next steps, with guidance anticipated by year-end.
Focus remains on advancing dialogue with FDA and exploring strategic opportunities to maximize the value of the belapectin program.
Biomarker data across independent measures support the mechanistic rationale for Galectin-3 inhibition and highlight belapectin’s potential to favorably alter disease trajectory.
Commentary excerpts from earnings call transcripts provide management's perspective on performance, strategy, and outlook. Always review full transcripts for complete context.
Operational metrics provide insight into business drivers and customer engagement beyond traditional financial measures.